Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factors influencing SARS-CoV-2 antibody formation
2021-006877-44Phase 4Completed
- Sponsor
- Salzburg University of Applied Sciences
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran, ChAdOx1 nCoV-19 and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Salzburg University of Applied Sciences. Primary endpoint: SARS-CoV-2-specific IgG antibodies. Started Jan 2022; status: completed.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006877-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006877-44.